» Articles » PMID: 10401610

Dehydroepiandrosterone Protects Tissues of Streptozotocin-treated Rats Against Oxidative Stress

Overview
Date 1999 Jul 13
PMID 10401610
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic hyperglycemia in diabetes determines the overproduction of free radicals, and evidence is increasing that these contribute to the development of diabetic complications. It has recently been reported that dehydroepiandrosterone possesses antioxidant properties; this study evaluates whether, administered daily for three weeks per os, it may provide antioxidant protection in tissues of rats with streptozotocin-induced diabetes. Lipid peroxidation was evaluated on liver, brain and kidney homogenates from diabetic animals, measuring both steady-state concentrations of thiobarbituric acid reactive substances and fluorescent chromolipids. Hyperglycemic rats had higher thiobarbituric acid reactive substances formation and fluorescent chromolipids levels than controls. Dehydroepiandrosterone-treatment (4 mg/day for 3 weeks) protected tissues against lipid peroxidation: liver, kidney and brain homogenates from dehydroepiandrosterone-treated animals showed a significant decrease of both thiobarbituric acid reactive substances and fluorescent chromolipids formation. The effect of dehydroepiandrosterone on the cellular antioxidant defenses was also investigated, as impaired antioxidant enzyme activities were considered proof of oxygen-dependent toxicity. In kidney and liver homogenates, dehydroepiandrosterone treatment restored to near-control values the cytosolic level of reduced glutathione, as well as the enzymatic activities of superoxide-dismutase, glutathione-peroxidase, catalase. In the brain, only an increase of catalase activity was evident (p < .05), which reverted with dehydroepiandrosterone treatment. The results demonstrate that DHEA treatment clearly reduces oxidative stress products in the tissues of streptozotocin-treated rats.

Citing Articles

Low Serum Dehydroepiandrosterone Is Associated With Diabetic Kidney Disease in Men With Type 2 Diabetes Mellitus.

Zhang X, Xiao J, Li X, Cui J, Wang K, He Q Front Endocrinol (Lausanne). 2022; 13:915494.

PMID: 35784547 PMC: 9240345. DOI: 10.3389/fendo.2022.915494.


Effect of Tungstate Administration on the Lipid Peroxidation and Antioxidant Parameters in Salivary Glands of STZ-Induced Diabetic Rats.

de Souza D, de Souza E, da Silva Pedrosa M, Nogueira F, Simoes A, Nicolau J Biol Trace Elem Res. 2020; 199(4):1525-1533.

PMID: 32596802 DOI: 10.1007/s12011-020-02273-x.


Diabetic‑induced alterations in hepatic glucose and lipid metabolism: The role of type 1 and type 2 diabetes mellitus (Review).

Jiang S, Young J, Wang K, Qian Y, Cai L Mol Med Rep. 2020; 22(2):603-611.

PMID: 32468027 PMC: 7339764. DOI: 10.3892/mmr.2020.11175.


Anabolic Hormone Deficiencies in Heart Failure with Reduced or Preserved Ejection Fraction and Correlation with Plasma Total Antioxidant Capacity.

Mancini A, Fuvuzzi A, Bruno C, Nicolazzi M, Vergani E, Ciferri N Int J Endocrinol. 2020; 2020:5798146.

PMID: 32411227 PMC: 7199626. DOI: 10.1155/2020/5798146.


Dehydroepiandrosterone Prevents HO-Induced BRL-3A Cell Oxidative Damage through Activation of PI3K/Akt Pathways rather than MAPK Pathways.

Li L, Yao Y, Jiang Z, Zhao J, Cao J, Ma H Oxid Med Cell Longev. 2019; 2019:2985956.

PMID: 31182991 PMC: 6512062. DOI: 10.1155/2019/2985956.